Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2021 Jun 12

PMID 34117592

Citations 5

Authors

Marla J Husnik

Elizabeth R Brown

Sufia S Dadabhai

Zakir Gaffoor

Nitesha Jeenarain

Flavia Matovu Kiweewa

Edward Livant

Leila E Mansoor

Brenda Gati Mirembe

Thesla Palanee-Phillips

Devika Singh

Samantha Siva

Lydia Soto-Torres

Ariane van der Straten

Jared M Baeten

Affiliations

Soon will be listed here.

Abstract

Understanding characteristics associated with adherence to pre-exposure prophylaxis (PrEP) methods for HIV-1 prevention may assist with optimizing implementation efforts. The dapivirine vaginal ring is a novel topical PrEP delivery method. Using data from a randomized, double-blind, placebo-controlled, phase III trial of the dapivirine vaginal ring conducted in four African countries, generalized estimating equation models were used to evaluate correlates of ring adherence. Two levels of quarterly dapivirine blood plasma, and dapivirine released from returned rings defined measures of adherence for recent and cumulative use, respectively. Time on study, calendar time, primary partner knowledge that the participant was taking part in the study, and use of long-acting contraceptive methods were associated with ring adherence whereas younger age, ring worries, condom use, episodes of menstrual bleeding and vaginal washing were associated with non-adherence. These findings may be useful for recruitment into future clinical studies and dapivirine ring implementation efforts.

Citing Articles

Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial.

Ngure K, Browne E, Reddy K, Friedland B, van der Straten A, Palanee-Phillips T AIDS Behav. 2024; 28(9):2990-3000.

PMID: 38852114 PMC: 11572767. DOI: 10.1007/s10461-024-04382-3.

How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.

Roberts S, Mancuso N, Williams K, Nabunya H, Mposula H, Mugocha C J Int AIDS Soc. 2023; 26(11):e26189.

PMID: 37936551 PMC: 10630658. DOI: 10.1002/jia2.26189.

Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.

Gati Mirembe B, Cabrera M, van der Straten A, Nakalega R, Cobbing M, Mgodi N AIDS Behav. 2022; 27(3):1030-1043.

PMID: 36066762 PMC: 10102709. DOI: 10.1007/s10461-022-03841-z.

Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.

Browne E, Brown E, Palanee-Phillips T, Reddy K, Naidoo L, Jeenarain N J Acquir Immune Defic Syndr. 2022; 90(4):418-424.

PMID: 35344520 PMC: 9342948. DOI: 10.1097/QAI.0000000000002990.

Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.

Shapley-Quinn M, Laborde N, Luecke E, Hoesley C, Salata R, Johnson S AIDS Patient Care STDS. 2022; 36(3):97-105.

PMID: 35289688 PMC: 8971982. DOI: 10.1089/apc.2022.0002.

References

Podsadecki T, Vrijens B, Tousset E, Rode R, Hanna G . "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008; 9(4):238-46. DOI: 10.1310/hct0904-238. View

Donnell D, Baeten J, Bumpus N, Brantley J, Bangsberg D, Haberer J . HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66(3):340-8. PMC: 4059553. DOI: 10.1097/QAI.0000000000000172. View

Evans D, Menezes C, Mahomed K, Macdonald P, Untiedt S, Levin L . Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses. 2013; 29(6):892-900. PMC: 3653371. DOI: 10.1089/AID.2012.0215. View

Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, van Niekerk N . A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014; 28(10):1479-87. DOI: 10.1097/QAD.0000000000000280. View

. The Joint United Nations Programme on HIV / AIDS (UNAIDS). Project update. Pac AIDS Alert Bull. 2002; (18):15-6. View

Nel A, van Niekerk N, Kapiga S, Bekker L, Gama C, Gill K . Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. N Engl J Med. 2016; 375(22):2133-2143. DOI: 10.1056/NEJMoa1602046. View

Mensch B, Richardson B, Husnik M, Brown E, Kiweewa F, Mayo A . Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE. AIDS Behav. 2018; 23(2):504-512. PMC: 6374159. DOI: 10.1007/s10461-018-2261-8. View

Spence P, Nel A, van Niekerk N, Derrick T, Wilder S, Devlin B . Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal. 2016; 125:94-100. PMC: 4873601. DOI: 10.1016/j.jpba.2016.03.023. View

Montgomery E, van der Straten A, Cheng H, Wegner L, Masenga G, Von Mollendorf C . Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012; 16(7):1787-98. DOI: 10.1007/s10461-012-0248-4. View

10.

Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74. PMC: 3001187. DOI: 10.1126/science.1193748. View

11.

van der Straten A, Montgomery E, Cheng H, Wegner L, Masenga G, Von Mollendorf C . High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012; 16(7):1775-86. DOI: 10.1007/s10461-012-0215-0. View

12.

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

13.

van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F . Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014; 9(2):e89118. PMC: 3931679. DOI: 10.1371/journal.pone.0089118. View

14.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

15.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

16.

Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J . Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. J Acquir Immune Defic Syndr. 2015; 71(4):452-61. DOI: 10.1097/QAI.0000000000000880. View

17.

Weinrib R, Minnis A, Agot K, Ahmed K, Owino F, Manenzhe K . End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa. AIDS Behav. 2017; 22(1):133-145. PMC: 5758675. DOI: 10.1007/s10461-017-1911-6. View

18.

van der Straten A, Browne E, Shapley-Quinn M, Brown E, Reddy K, Scheckter R . First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring. J Acquir Immune Defic Syndr. 2019; 81(3):304-310. PMC: 6571014. DOI: 10.1097/QAI.0000000000002028. View

19.

Baeten J, Palanee-Phillips T, Brown E, Schwartz K, Soto-Torres L, Govender V . Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375(22):2121-2132. PMC: 4993693. DOI: 10.1056/NEJMoa1506110. View

20.

Blanc A, Tsui A, Croft T, Trevitt J . Patterns and trends in adolescents' contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health. 2009; 35(2):63-71. DOI: 10.1363/ipsrh.35.063.09. View